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ABSTRACT 
Introduction 
The majority of older patients with a transtibial amputation are prescribed a standard (more rigid, 
not self-aligning) prosthesis. These are mostly suitable for level walking, and cannot adjust to 
different sloped surfaces. This makes walking more difficult and less energy efficient, possibly 
leading to longer term disuse. A Cochrane Review concluded there was insufficient evidence to 
recommend any individual type of prosthetic ankle-foot mechanism. This trial will establish the 
feasibility of conducting a large scale trial to assess the effectiveness and cost-effectiveness of a self-
aligning prosthesis for older patients with vascular-related amputations and other health issues, 
compared to a standard prosthesis. 
 
Methods and analysis 
This feasibility trial is a pragmatic, parallel group, randomised controlled trial (RCT) comparing 
standard treatment with a more rigid prosthesis versus a self-aligning prosthesis. The target sample 
size is 90 patients, who are aged 50 and over, and have a transtibial amputation, where amputation 
aetiology is mostly vascular-related or non-traumatic. Feasibility will be measured by: consent and 
retention rates, a plausible future sample size over a 24-month recruitment period, and 
completeness of outcome measures. Qualitative interviews will be carried out with trial participants 
to explore issues around study processes and acceptability of the intervention. Focus groups with 
staff at prosthetics centres will explore barriers to successful delivery of the trial. Findings from the 
qualitative work will be integrated with the feasibility trial outcomes in order to inform the design of 
a full-scale RCT. 
 
Ethics and dissemination  
Ethical approval was granted by Yorkshire & the Humber - Leeds West Research Ethics Committee 
on 4 May 2018. The findings will be disseminated via peer-reviewed research publications, articles in 
relevant newsletters, presentations at relevant conferences and the patient advisory group.   
 
Trial registration 
ISRCTN15043643 
 
Keywords 
Randomised controlled trial, feasibility, amputation, prosthesis, acceptability, vascular  
 
Protocol version 
Version 1.3, 27th November 2018 
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ARTICLE SUMMARY 
Strengths and limitations of this study 
- This will be one of few studies involving older amputees in research. 
- Should it be determined that a larger scale RCT is feasible, the information collected in this 
study will be vital in influencing the design.  
- The proposed sample size is large enough to allow for reliable estimates to be obtained for 
calculating a future sample size for a main trial. 
- The study is not large enough to determine effectiveness and is limited to only assess the 
feasibility aspect.  
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INTRODUCTION 
The number of people with a lower limb amputation is growing and is predicted to double in 
developed nations by the year 2050 (1). In the UK, there are approximately 6,000 new 
referrals to prosthetics services every year, most commonly at the transtibial level (2, 3). 
Most lower limb amputations (60-80%) are related to ischemia, vascular atherosclerotic 
disease and diabetic complications, and typically occur in people over 50 years of age (3, 4). 
A retrospective review of hospital data in England reported that there were 25,312 lower 
limb amputations for patients aged between 50-84 years between 1 April 2003 and 31 
March 2009 (5). Therefore, most new referrals for a prosthesis involve older patients who 
usually present with multiple health comorbidities.  
 
Prosthetic prescription, one important factor in the long-term outcomes following 
amputation, is multifaceted, and influenced by factors such as estimation of patient 
outcomes, patient goals, and budget (6). Practice varies across UK prosthetics centres and is 
frequently cost-driven. In December 2016, NHS England issued its Clinical Commissioning 
Policy guidelines for the routine prescription of microprocessor-controlled prosthetic knees 
for people with a transfemoral amputation (7). The recent clinical commissioning policy is 
ground-breaking for people with a transfemoral amputation, but presents no advantage for 
the prescription of a prosthesis for individuals with an amputation at the transtibial level. A 
Cochrane Review concluded there was insufficient evidence from “high quality comparative 
studies for the overall superiority of any individual type of prosthetic ankle-foot 
mechanism” in patients with a lower limb amputation (8). Subsequently, the majority of 
older people with a transtibial amputation, often due to vascular reasons, are prescribed a 
standard prosthesis, such as the non-articulated solid ankle cushioned heel (SACH), uniaxial 
or multiaxial prosthetic foot. These prostheses are unable to adjust to the different walking 
surfaces people encounter daily (i.e., uneven terrain, slopes and stairs). This makes walking 
more difficult, less energy efficient and more tiring, and may lead to longer term disuse.  
 
Lower limb amputation, and its associated health comorbidities (i.e., disease status, age- 
and amputation-related complications, pain and sedentary behaviour), present a burden for 
patients (and their carers). Patients often report having problems related to mobility, which 
subsequently impacts negatively on their independence, and socioeconomic well-being (9, 
10), especially among older, vascular amputees (11). Identifying a suitably functional 
prosthesis could bring many benefits to a patient’s life following amputation.  
 
People with a lower limb amputation are an under-represented group of patients, with little 
research being carried out involving those aged over 50 years. We carried out a number of 
public involvement sessions in order to refine our study aims and identify elements of 
particular resonance with older individuals following their amputation. Public involvement 
members, who experienced reduced mobility, identified their standard prosthesis as a 
limiting factor in their everyday function. A poorly functioning prosthesis often contributed 
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to sedentary behaviour, pain, more frequent visits to healthcare services, disuse of the 
prosthesis and possible isolation, and overall poor quality-of-life.  
 
In order to clearly identify an amputee’s current and potential functional status the 
insurance group, Medicare, established Medicare Functional Classification Levels (MFCL; 
also called K levels) in 1995, which is widely used internationally. It is a method of 
quantifying need and the potential benefit of prosthetic devices for those with a lower limb 
amputation. Five classification levels (K0: low functional level to K4: high functional level) 
were established (12). An alternative classification system is the SIGAM (Special Interest 
Group in Amputee Medicine) developed by the British Society of Rehabilitation Medicine 
which measures levels of mobility (grade A: lowest mobility to grade F: highest 
mobility)(13). A self-aligning prosthesis has been designed specifically for the K2 user, 
categorised as ‘limited mobility’, to alleviate many of the patient-reported limitations of a 
standard prosthesis. This prosthesis adjusts to slopes and steps via hydraulic mechanisms. A 
self-aligning prosthesis can improve ground clearance to avoid a fall, and aligns to secure 
the biological knee in individuals with a transtibial amputation, which is important for falls 
prevention (14). Based on laboratory studies, this type of self-aligning prosthesis also has 
demonstrated reduced residuum-socket interface pressures (15), which could alleviate pain 
in the residuum longer-term. Although a self-aligning prosthesis is more expensive than a 
standard prosthesis (by approximately £800), the potential patient benefits through 
increased mobility, quality-of-life, and fewer falls could offset future healthcare and 
socioeconomic costs. Previous studies have shown that more functional prostheses may 
offer better patient function and improve mobility in people with a lower limb amputation 
(16, 17). However, these studies have not been undertaken in older patients and therefore 
have not considered the health comorbidities that affect older, often vascular, patients 
compared to younger, more active amputees.  
 
METHODS AND ANALYSIS 
Aim and objectives 
The primary aim of this study is to determine the feasibility of conducting a full-scale 
randomised controlled trial (RCT) of the effectiveness and cost-effectiveness of a self-
aligning prosthesis for older patients with vascular-related amputations and other health 
issues compared to a standard prosthesis.  
 
The specific objectives are to: 
• determine patient recruitment rates; 
• explore any barriers to recruitment and how these might be overcome from the 
perspective of patients;  
• identify the most important outcomes to the patients; 
• assess the acceptability of the study procedures to both participants and recruiting 
centres; 
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• measure patient use of NHS resources over the study period;  
• identify a primary outcome measure(s) for a future main trial; 
• assess the completeness of follow-up data, to establish how feasible it is to collect 
patient-reported outcome measures; 
• Measure day-to-day use of the prosthesis in both groups and measure normal 
physical activity through the use of wearable technologies (activity monitors). 
 
In addition, the feasibility of a future trial will be assessed based on whether: 
• study consent/retention rates and proposed sample sizes indicate recruitment for 
the full-scale RCT is plausible within a 24-month period; 
• outcome measures and fidelity evaluation data are successfully collected;  
• there are no significant barriers to delivery of the trial identified by participants or 
recruiting centres, that cannot be overcome.  
 
Design 
The STEPFORWARD trial is a multi-centre, mixed-methods, randomised controlled, open 
feasibility trial to assess the possibility of conducting a full-scale RCT of a self-aligning 
prosthesis for older patients with vascular-related amputations and other health issues 
compared to a standard prosthesis. The two-year study commenced on 1 April 2018; 
participant recruitment started in July 2018. 
 
Settings and participants 
Participants who meet the eligibility criteria are being recruited from multiple centres based 
in NHS Trusts across England.  
 
Inclusion criteria  
A patient is deemed eligible if they meet all the following criteria: 
1) Aged 50 years or over 
2) Has a unilateral amputation 
3) Has a transtibial amputation only  
4) Has an amputation due to vascular reasons (e.g., diabetes, peripheral vascular 
disease), neurological disorders (e.g., diabetic neuropathy) or life-limiting illness 
(e.g., tumour, cancer) 
5) Is categorised as ‘limited mobility’: K2 classification, or SIGAM mobility grade C or D 
6) Is currently using a standard prosthetic ankle-foot (e.g., SACH, uniaxial, multiaxial 
(e.g., multiflex) or other K1/K2 feet) that does not adjust to sloped surfaces and is 
not self-aligning 
7) Has been using a prosthesis for at least 12 months, with the same socket for a 
minimum of three months 
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8) Has had a stable residual limb for at least three months (i.e. stable in volume and 
without cuts or wounds; daily management of volume with socks and liners is 
acceptable) 
9) Is willing to trial a new prosthesis for a 12-week period (if allocated to intervention 
arm) 
10) Is able to self-complete the English language outcome measure tools (or complete 
with assistance) 
11) Is able to follow the detailed verbal instructions required for the functional/clinical 
tests 
12) Is able to provide written informed consent 
 
Exclusion criteria 
Patients will be considered ineligible if any of the following apply:  
1) Has contraindications of wearing their current prosthesis (e.g., open wound, 
infection) 
2) Has contraindications of wearing the novel prosthesis according to manufacturer’s 
instructions (e.g., body mass ≥ 150 kg; build height (i.e. distance between distal end 
of socket and ground) less than 115mm) 
3) Has had a recent cerebrovascular event, such as a stroke 
4) Has a disease that severely affects their memory, such as dementia or Alzheimer’s 
 
Sample size  
This research is a feasibility RCT and therefore does not have a primary outcome measure to 
inform a power calculation. Sample sizes of between 24 and 70 have been recommended 
for feasibility trials to allow for the reliable estimation of a standard deviation for use in 
future sample size calculations (18, 19). We plan to recruit a total of 90 patients in this study 
over a 16-month timeframe. Allowing for a 20% attrition rate we intend to have 72 patients 
in the final analysis.  
 
Randomisation 
Following the completion of all baseline measures, participants will be randomised into one 
of two trial arms: standard prosthesis (standard treatment) or self-aligning prosthesis (novel 
treatment). Randomisation will be performed by the York Trials Unit. Participants will be 
individually randomised and stratified according to prosthetics centre on a 1:1 basis. 
 
Blinding  
By the nature of the interventions used within this study, blinding of the participants and 
investigators is not possible and procedures for breaking codes/un-blinding are not 
necessary.  
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Intervention and standard treatment 
Novel treatment: The self-aligning ankle-foot prosthesis is called the Avalon-K2, 
manufactured by Blatchford & Sons, UK (Patent reg: 5336386). The prosthesis is already 
commercially available and may be prescribed under the NHS. 
 
Following randomisation, participants in the novel treatment group will have an initial 
meeting with their regular prosthetist for fitting of the novel prosthesis. Once fitted with the 
self-aligning prosthesis, participants will be asked to acclimatise and ambulate with it as 
they would normally with any new prosthesis for approximately 12 weeks after fitting 
(intervention period). They will be offered physiotherapy sessions, to ensure their ability to 
ambulate safely with the new prosthesis, based on clinical need.  
 
Participants in the novel treatment group will be given the option to keep using the novel 
prosthesis after the trial has completed or return to their original prosthesis.  
 
Standard treatment: Participants in the standard treatment group will continue using their 
normal ankle-foot prosthesis. Participants in this group will continue to receive standard 
treatment and have access to all clinical services as normal. Standard treatment usually 
consists of routine visits to the consultant and/or patient-initiated visits (i.e., normal 
prosthetics maintenance, and/or trouble-shooting due to prosthesis malfunction). This 
group will be asked to go about their normal daily routine wearing their standard prosthesis 
for 15 weeks (intervention period plus additional three weeks to allow for ordering and 
fitting of new prosthesis for participants in the novel group). 
 
Participants in the standard treatment group will not be offered to sample the self-aligning 
prosthesis at the end of the trial as it is not known whether the novel prosthesis is better 
and more acceptable to patients than the standard prosthesis. 
 
Participant identification and recruitment process 
All patients with a unilateral, transtibial amputation due to non-traumatic reasons will be 
screened for eligibility. The practicalities of using the eligibility criteria will be assessed to 
inform the criteria that may be subsequently used in a main trial. Prospective participants 
will be identified via two main methods: during a routine clinical visit or via screening of the 
patient database (see Figure 1) 
 
In clinic: Potentially eligible patients attending for their routine appointment to the 
prosthetics centre will be approached and given a study invitation pack. Patients may 
complete a Consent to Contact form during their routine appointment, and be screened by 
a member of their Multidisciplinary Team (MDT) as soon as possible thereafter. 
Alternatively, patients may take the pack away to read through, and return their Consent to 
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Contact form in the post. Then the enrolment process will follow the one outlined for those 
identified via database screening. 
 
Database screening: A member of the patient’s routine MDT and/or prosthetics centre 
manager will screen the prosthetics centre’s database for suitable patients according to the 
inclusion criteria. Potential participants will be posted a study invitation pack. They will be 
asked to read through the documents and return the Consent to Contact form if they wish 
to be contacted about the trial. If no Consent to Contact form is received, patients will be 
contacted by the prosthetics centre approximately two weeks after expected receipt of the 
invitation pack. 
 
Alternatively, upon receipt of the patient’s Consent to Contact form, a member of the MDT 
will contact the patient and complete the first section of the Screening Form over the 
telephone. If potentially eligible, the patient will be invited to make an appointment in clinic 
for a face-to-face screening to check eligibility and complete the outstanding screening 
questions. If eligible, patients will follow the consent process.  
 
Some patients may not meet all of the inclusion criteria at the initial screening and would be 
eligible for a re-screen for two reasons: patient has not yet had a stable residual limb for at 
least three months, or they presently have a contraindication for wearing their current 
prosthesis. They will be contacted after three months to re-assess their eligibility unless they 
explicitly request otherwise. Patients will only be re-screened for eligibility once.  
 
Study visits and follow-up 
Data will be collected from participants at four time points:  
 
Screening visit: Initial screening may be conducted by telephone, but all prospective 
participants must have a final face-to-face screening at their prosthetics centre by a 
member of their normal MDT for eligibility. Informed consent will be sought from eligible 
patients by an MDT member and according to Good Clinical Practice guidelines.  
 
Baseline assessment: All consenting participants will be asked to complete a baseline 
questionnaire and undergo four clinical assessments at the prosthetics centre. They will be 
loaned an activity monitor (activPAL4TM, PAL Technologies Ltd, Glasgow, UK), which will be 
fitted onto their prosthesis for one week after the baseline assessment. After this they will 
be requested to remove it and return it via post. The activity monitor will quantify the time 
spent during walking activities and the number of daily steps taken, using their standard 
prosthesis.  
 
STEPFORWARD_Protocol Paper_201907017  10 
 
Interim follow-up: All participants will be posted a questionnaire pack mid-way through the 
intervention period (week 9 post-randomisation). They will be asked to complete and return 
the questionnaires in a pre-paid return envelope.  
 
Final follow-up: Participants will be posted an activity monitor in the week prior to their final 
follow-up assessment (15 weeks post-randomisation), and asked to fit the activity monitor 
onto their prosthesis to monitor their daily stepping with the prosthesis they are currently 
using. The activity monitor will be removed when the participant attends the prosthetics 
centre for their final study visit. Participants will also be asked to complete the same 
questionnaire and clinical assessments as they did at baseline. 
 
Outcome measures 
Table 1 details the information to be collected according to time points. The participant 
questionnaires include: 
• Locomotor Capabilities Index-5 (LCI-5) (20); 
• Houghton Scale – prosthetic use in people with lower-extremity amputations (21); 
• Patient-Reported Outcomes Measurement Information System (PROMIS) Short-
Form v1.0 Pain (3a and 8a) questionnaires (22); 
• EQ-5D-5L (23) 
• Bespoke health resource use questionnaire. 
 
The four clinical assessments will be carried out at baseline with the participant wearing 
their standard prosthesis and repeated at final follow-up, wearing whichever prosthesis they 
are using at the time. Participants may also use their regular walking aid and choose not to 
attempt some assessments. The assessments are: 
• 2-minute walk test (2mWT) (24). 
• Timed-Up and Go test (TUG) (25); 
• Timed-Up and Down test (TUDS) (26); 
• Berg Balance Scale (BBS) (27); 
 
Qualitative data collection 
Semi-structured interviews will be undertaken with 20-25 participants to explore their 
experience of being involved in the trial, acceptability of the study design, randomisation 
and other study processes, and acceptability of the intervention. Participants will be 
purposively selected, we aim to sample approximately 8-10 participants from each of the 
novel prosthesis and standard prosthesis arms, and approximately five patients who 
declined to participate or dropped out of the trial to explore reasons for non-participation. 
We appreciate that the non-participant group may be difficult to reach and will only 
approach individuals who, at the time they declined to participate, indicated they were 
happy to be contacted with a view to being potentially interviewed. Purposive selection will 
ensure maximum variation across the sample with regards to age, and gender. The 
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proposed sample of interviewees is likely to achieve data saturation whereby similar themes 
emerge (28, 29). A flexible interview schedule will be developed.  
 
Focus groups will also be conducted with staff (including clinicians, physiotherapists, 
prosthetists, centre managers) at each participating prosthetics centre to discuss any 
barriers to successful delivery of the trial. Findings from the qualitative work will be 
integrated with the feasibility trial outcomes in order to inform the design of a full-scale 
RCT. 
 
All interviews and focus groups will be audio recorded with permission. Recordings will be 
transcribed verbatim by approved transcribers and anonymised. A second researcher will 
check a sample of data transcripts against the audio recordings for accuracy, and will 
interrogate the validity of the coding against the raw data. Data will be entered into 
appropriate software for thematic analysis. 
 
Statistical analyses 
A statistical analysis plan (SAP) detailing intended analyses will be drafted before the 
completion of data collection. The trial will be reported according to the CONSORT 
guidelines for feasibility and pilot trials and the flow of participants through the trial will be 
detailed in a CONSORT flow diagram.  
 
Baseline data will be summarised by trial arm, as randomised, with no formal comparison 
between the groups. Continuous data will be reported descriptively (mean, standard 
deviation, median, minimum, maximum and number missing), and categorical data by 
counts and percentages. No formal statistical analyses will be undertaken as this is a 
feasibility study. Completion rates of all the clinical outcome measures will be reported by 
trial arm and overall. 
 
The recruitment rate will be reported monthly, and overall, by centre. An average monthly 
recruitment rate will be calculated, and a 95% confidence interval (CI) will be estimated 
from the data collected. This could be used to inform recruitment rates per site in a future 
main trial and determine if an adequate sample could be recruited in ≥24 months in a larger 
trial. The number of eligible patients will be summarised overall, by site, using counts and 
percentages. Reasons for ineligibility will be detailed in the CONSORT diagram. The 
following will also be reported, the proportion of:  
- eligible patients approached for consent;  
- patients approached who provide consent;  
- patients approached who do not provide consent;  
- patients providing consent who are randomised;  
- patients dropping out between randomisation and follow-up.  
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Health economic analysis 
A full cost-effectiveness analysis will not be undertaken as part of the current study. Rather, 
the work will identify the feasibility of collecting the data, needed for an economic analysis 
of a full-scale trial. Health service resource use will be collected from participants using a 
bespoke questionnaire that will include items such as hospital attendances and admissions 
and also primary care visits (e.g., GP, physiotherapist and prosthetist). The costing approach 
will be undertaken from an NHS perspective and unit costs will be derived from established 
national costing sources such as NHS Reference Costs(30) and Personal Social Services 
Research Unit costs of health and social care(31). The costs of providing the novel prosthesis 
will be estimated and the potential resource implications versus the standard prosthesis will 
be explored. 
 
Safety measurements 
Adverse events (AEs) related to the prosthesis only, and any serious adverse event (SAE), 
will be recorded throughout the study. Intensity and relationship to the study intervention 
will be described. Ongoing review of AEs and SAEs will take place during monthly Trial 
Management Group (TMG) meetings, discussed with the Patient Advisory Group (PAG) and 
Trial Steering Committee (TSC), and reported to the sponsor and ethics committee in line 
with their guidelines. Participants may withdraw from the study at any time without 
influencing their future care or treatment. 
 
Trial monitoring and oversight 
Due to the low risk nature of this trial there will be one independent steering and 
monitoring committee to undertake the roles traditionally undertaken by the TSC and Data 
Monitoring and Ethics Committee. This Trial Steering and Monitoring Committee will 
comprise of independent members including a Chair, a statistician, one other independent 
person and a member of the PAG. 
 
The TMG, comprising the chief investigator, the York Trials Unit and co-investigators, will 
provide overall management of the study. York Trials Unit is responsible for project 
management. We will establish a Project Advisory Group (PAG) with between 4-8 members 
that will meet a minimum of five times over the duration of the project. The PAG is a group 
of independent patients with an amputation and their carers, whose role is to support and 
advise the TMG on all aspects of the study and to facilitate its progress and management. 
 
Patient and public involvement 
Three funded patient and public involvement (PPI) events were carried out at the recruiting 
sites to inform the development of this study. The PPI events helped to identify the 
objectives for the feasibility study, specify outcomes that are significant to this patient 
population, and share views on the randomisation process. This has enabled the team to 
prioritise outcome measures related to amputee patient function and well-being, and 
STEPFORWARD_Protocol Paper_201907017  13 
 
explore how to introduce the study to potential participants while taking into account their 
valid concerns about randomisation. 
 
Data collection, integrity and management  
Data will be collected through paper questionnaires identified by a unique identification 
number only (i.e., the participant identification number in all manual and electronic files). 
Each site will hold data according to the General Data Protection Regulation (May 2018). A 
Trial Enrolment Log at the sites will list the participant identification numbers. York Trials 
Unit will maintain a list of participant identification numbers for all trial patients at each site. 
 
All paper documents will be stored securely. All information collected will be stored on a 
secure password-protected server located at the University of York, for the purposes of 
assisting in follow-ups during the study and will be kept strictly confidential. 
 
The confidentiality of participants and staff interviewed during the qualitative interviews 
will be ensured by assigning a unique participant number to electronic sound files and 
transcripts, known only to the qualitative researcher and appropriate members of the 
research team. Any quotes published will be anonymous. All data collected will be archived 
for ten years following the end of the study. 
 
Ethics and dissemination  
Yorkshire & The Humber - Leeds West Research Ethics Committee granted ethical approval 
for this study on 4th May, 2018. Since the study started, the Health Research Authority 
(HRA) approved three substantial amendments to the protocol which are included in the 
final version reported here:  
1. Inclusion of clear written and pictorial instructions for fitting the activity monitor to 
the participant’s prosthesis.  
2. Alteration to the recruitment process such that staff at the local prosthetics centre 
could contact a potential participant after invitations packs had been sent to them.  
3. Inclusion of a cover letter to accompany the participant information sheet for the 
qualitative interview aspect of the study. 
The proposed study will be conducted in accordance with the Medical Research Council 
Guidelines on Good Clinical Practice in Clinical Trials. 
 
The results will inform the design and delivery of a definitive RCT. The findings from this 
study will be presented to relevant groups such as the British Association of Chartered 
Physiotherapists in Amputee Rehabilitation (BACPAR) and the British Association of 
Orthotists and Prosthetists (BAPO). Participants will be informed of the outcome of the 
study. With the help of our PAG representatives, the findings will be disseminated to 
participants, other patients and their carers, and relevant patient support groups, including 
national charities supporting individuals following limb loss. The results will also be 
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submitted to the funders, peer-reviewed journals, presented at relevant 
meeting/conferences, including participating recruitment sites. 
 
Conclusion 
There is limited robust evidence about the benefits of prescribing a self-aligning prosthesis 
for patients over the age of 50, who are predominantly prescribed a standard (i.e., more 
rigid) prosthesis. The outcomes from this study will inform a larger fully powered RCT 
designed to determine the effectiveness of a self-aligning prosthesis in improving a patient’s 
daily mobility.  
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Figure legend 
 
Figure 1: The STEPFORWARD study flowchart 
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Table 1. Trial activity and data collection time points 
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Consent  X     
Questionnaires        
Demographics  X     
LCI-5  X  X  X 
Houghton  X  X  X 
EQ-5D-5L  X  X  X 
PROMIS 3a & 8a  X  X  X 
Health care resource use  X  X  X 
Clinical assessments       
2mWT   X    X 
TUG  X    X 
TUDS  X    X 
BBS  X    X 
One week activity monitor  X   X  
Novel prosthesis treatment 
group only 
  X    
 
BBS: Berg Balance Scale; LCI-5: Locomotor Capabilities Index-5; PROMIS: Patient-Reported 
Outcomes Measurement Information System; TUDS: Timed Up and Down Stair test; TUG: 
Timed Up and Go test  
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